Who founded Inventprise?

Inventprise was founded by Subhash Kapre in 2012.

How much funding has Inventprise raised?

Inventprise has disclosed $3.5M raised across 1 round.

Where is Inventprise headquartered?

Inventprise is headquartered in Redmond, US.

Inventprise

Redmond, US · Founded 2012 · Washington LLC · 91 employees on LinkedIn

Inventprise is a clinical-stage vaccine developer using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform to create conjugate vaccines, including a lead pediatric pneumococcal conjugate vaccine (IVT PCV-25) and candidates for Group B Streptococcus and mRNA-based vaccines. The company also operates automated manufacturing facilities intended to supply global vaccine demand.

Biotech Healthtech

Founders & leadership

Inventprise was founded in 2012 by Subhash Kapre.

Subhash KapreManager, Co-CEO

Pradip GhateChief Operating Officer

David GoeslingChief Financial Officer

Yves LeurquinManager, Co-CEO

Reported raises · per SEC filings

Form D private placements

$3.5M disclosed across 1 round · 2021

▶$3.5MraisedNov 2021 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Pradip GhateExecutive Officer
David GoeslingExecutive Officer
Subhash KapreExecutive Officer, Director
Yves LeurquinExecutive Officer

Offering amount: $95M
Amount sold: $3.5M
First sale: Nov 2021
Incorporated: Limited Liability Company, Washington
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

IQVIA11 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.

Vaxcyte11 shared keywordsVaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.

Companies competing with Inventprise for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Inventprise do?: Inventprise is a clinical-stage vaccine developer using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform to create conjugate vaccines, including a lead pediatric pneumococcal conjugate vaccine (IVT PCV-25) and candidates for Group B Streptococcus and mRNA-based vaccines. The company also operates automated manufacturing facilities intended to supply global vaccine demand.
Who founded Inventprise?: Inventprise was founded by Subhash Kapre in 2012.
How much funding has Inventprise raised?: Inventprise has disclosed $3.5M raised across 1 round.
Where is Inventprise headquartered?: Inventprise is headquartered in Redmond, US.